Cerity Partners LLC Reduces Stock Position in Sanofi (NASDAQ:SNY)

Cerity Partners LLC decreased its stake in Sanofi (NASDAQ:SNY - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 121,028 shares of the company's stock after selling 6,055 shares during the period. Cerity Partners LLC's holdings in Sanofi were worth $6,138,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. State Street Corp lifted its holdings in shares of Sanofi by 0.5% in the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after purchasing an additional 264 shares during the last quarter. EP Wealth Advisors LLC lifted its stake in Sanofi by 47.7% in the third quarter. EP Wealth Advisors LLC now owns 7,895 shares of the company's stock valued at $455,000 after buying an additional 2,548 shares during the last quarter. Barclays PLC boosted its holdings in shares of Sanofi by 107.5% in the third quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after acquiring an additional 331,445 shares during the period. Geode Capital Management LLC increased its holdings in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock valued at $14,681,000 after acquiring an additional 16,780 shares during the period. Finally, Coldstream Capital Management Inc. boosted its stake in Sanofi by 16.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 6,081 shares of the company's stock worth $350,000 after purchasing an additional 866 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Sanofi Price Performance

Sanofi stock traded down $0.04 during midday trading on Wednesday, reaching $50.56. The company's stock had a trading volume of 5,640,036 shares, compared to its average volume of 2,361,421. The stock's 50 day simple moving average is $54.89 and its 200 day simple moving average is $52.30. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market capitalization of $127.73 billion, a PE ratio of 20.31, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on SNY. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday. They issued an "outperform" rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.